Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).

被引：6
|
作者：
Bahlis, Nizar J.
Moreau, Philippe
Nahi, Hareth
Plesner, Torben
Goldschmidt, Hartmut
Suzuki, Kenshi
Orlowski, Robert Z.
Rabin, Neil
Leiba, Merav
Oriol, Albert
Chari, Ajai
Miguel, Jesus San
Richardson, Paul G.
Usmani, Saad Zafar
O'Rourke, Lisa Marie
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Qin, Xiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8025
引用
收藏
页数：5
相关论文
共 50 条
  • [1] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)
    Moreau, P.
    White, D.
    Benboubker, L.
    Cook, G.
    Leiba, M.
    Morton, J.
    Ho, P. J.
    Kim, K.
    Takezako, N.
    Trivedi, S.
    Wu, K.
    Casneuf, T.
    Chiu, C.
    Schecter, J. M.
    Dimopoulos, M. A.
    [J]. HAEMATOLOGICA, 2018, 103 : 31 - 31
  • [2] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lofti
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Trivedi, Sonali
    Wu, Kaida
    Casneuf, Tineke
    Chiu, Christopher
    Schecter, Jordan
    Moreau, Philippe
    [J]. BLOOD, 2017, 130
  • [3] Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX
    San-Miguel, Jesus
    Dimopoulos, Meletios Athanasios
    Usmani, Saad
    Belch, Andrew R.
    Bahlis, Nizar J.
    White, Darrell J.
    Benboubker, Lofti
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Kaufman, Jonathan L.
    Sutherland, Heather
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Chari, Ajai
    Wu, Kaida
    Casneuf, Tineke
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E17 - E18
  • [4] Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX
    Dimopoulos, Meletios
    Belch, Andrew R.
    White, Darrell J.
    Benboubker, Lofti
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    San-Miguel, Jesus
    Moreau, Philippe
    Kaufman, Jonathan L.
    Sutherland, Heather
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Chari, Ajai
    O'Rourke, Lisa
    Wu, Kaida
    Casneuf, Tineke
    Chiu, Christopher
    Soong, David
    Qin, Xiang
    Sasser, Kate
    Khokhar, Nushmia
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E116 - E116
  • [5] EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX
    Dimopoulos, M. A.
    Moreau, P.
    Nahi, H.
    Plesner, T.
    Goldschmidt, H.
    Suzuki, K.
    Orlowski, R. Z.
    Rabin, N.
    Leiba, M.
    Oriol, A.
    Chari, A.
    San-Miguel, J.
    Richardson, P. G.
    Usmani, S. Z.
    O'Rourke, L.
    Wu, K.
    Casneuf, T.
    Chiu, C.
    Qin, X.
    Bahlis, N. J.
    [J]. HAEMATOLOGICA, 2017, 102 : 108 - 109
  • [6] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary E.
    Feng, Huaibao
    Brun, Nikolai Constantin
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    [J]. BLOOD, 2014, 124 (21)
  • [7] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
    Plesner, T.
    Arkenau, H. T.
    Lokhorst, H. M.
    Gimsing, P.
    Krejcik, J.
    Lemech, C.
    Minnema, M. C.
    Lassen, U.
    Ahmadi, T.
    Yeh, H.
    Guckert, M.
    Brun, N. C.
    Lisby, S.
    Basse, L.
    Palumbo, A.
    Richardson, P. G.
    [J]. HAEMATOLOGICA, 2014, 99 : 104 - 104
  • [8] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux
    Moreau, Philippe
    Oriol, Albert
    Kaufman, Jonathan L.
    Sutherland, Heather
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, Miles
    Cochrane, Tara
    O'Rourke, Lisa
    Wu, Kaida
    Schecter, Jordan M.
    Bahlis, Nizar J.
    [J]. BLOOD, 2017, 130
  • [9] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Belch, Andrew
    White, Darrell
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Sutherland, Heather J.
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Bahlis, Nizar J.
    Chari, Ajai
    O'Rourke, Lisa
    Wu, Kaida
    Schecter, Jordan M.
    Casneuf, Tineke
    Chiu, Christopher
    Soong, David
    Sasser, A. Kate
    Khokhar, Nushmia Z.
    Avet-Loiseau, Herve
    Usmani, Saad Z.
    [J]. HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
  • [10] This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX
    Dimopoulos, M. A.
    Oriol, A.
    Nahi, H.
    Miguel, J. S.
    Bahlis, N. J.
    Rabin, N.
    Orlowski, R.
    Komarnicki, M.
    Suzuki, K.
    Plesner, T.
    Samoilova, O. S.
    Yoon, S. S.
    Yehuda, D. B.
    Richardson, P. G.
    Goldschmidt, H.
    Reece, D.
    Khokhar, N.
    O'Rourke, L.
    Chiu, C.
    Qin, X.
    Guckert, M.
    Ahmadi, T.
    Moreau, P.
    [J]. HAEMATOLOGICA, 2016, 101 : 342 - 342
12345